anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Doxycycline hyclate delayed-release tablets USP, for oral administration, contain specially coated pellets of doxycycline hyclate, USP, a tetracycline class drug synthetically derived from oxytetracycline, in a delayed-release formulation for oral administration. 

The structural formula for doxycycline hyclate, USP is:  


The molecular formula is C22H24N2O8 •HCl •½ C2H6O •½ H2O and a molecular weight of 512.9. The chemical name for doxycycline hyclate, USP is 4-(dimethylamino)-1,4,4α,5,5α,6,11,12α-octahydro-3,5,10,12,  
12α-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacencarboxamide monohydrochloride, compound with ethyl alcohol (2:1), monohydrate. Doxycycline hyclate, USP is a yellow crystalline powder soluble in water and in solutions of alkali hydroxides and carbonates. Doxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form.

Each tablet contains doxycycline 50 mg or 200 mg equivalent to doxycycline hyclate 57.7 mg or 230.8 mg, respectively. Inactive ingredients in the tablet formulation are: crospovidone, D&C Yellow #10 Aluminum Lake, hypromellose 2910, hypromellose phthalate, magnesium stearate, mannitol, microcrystalline cellulose, povidone, silicified microcrystalline cellulose, talc, and triethyl citrate.

USP Dissolution test pending.
PURPOSE: Provided are a sperm surface antigen, a monoclonal antibody therefor, and applications for both the monoclonal antibody and the antigen. Specifically, a contraceptive vaccine is provided employing the antigen as an immunogen, as well as a standard for immunity assays, and the monoclonal antibody finds application as a spermicide and diagnostic reagent. CONSTITUTION: An onoclonal antibody S19, expressed by Deposit HB12144, ATCC, effectively agglutinates a sperm surface glycoprotein, SAGA-1 protein. The mAB finds utility as a binding agent in a spermicide, showing a high degree of effectiveness in binding potential sperm. The protein bound, identified as SAGA-1, is the immunogen in a contraceptive vaccine, as well as the standard for determining antibody titer upon vaccination. The monoclonal antibody can also be used as a diagnostic to determine the presence, and amount, of sperm in a variety of samples.
Individuals enrolled in Phase I and II will complete a Computerized Cognitive Training (CCT) based on an intervention with 15 different cognitive tasks in the form of games aimed at enhancing memory, attention, reasoning, perception and coordination skills. The CCT will be implemented in an app designed by CogniFit (CogniFit Inc., San Francisco, USA) to be used in tablets or mobile phones.
OBJECTIVE: To assess the effectiveness of a self-constructed modified apical negative pressure irrigation (ANPI) system employing commonly used clinical instruments in nonsurgical root canal therapy (NSRCT) for large cyst-like periapical lesions (LCPLs).
METHODS: From 2017 to 2022, 35 patients diagnosed with LCPLs (5-15 mm) via preoperative clinical and radiographic evaluations of endodontic origin underwent NSRCT combined with ANPI. These patients were subjected to postoperative clinical and radiographic follow-up at 3 months, 6 months, 1 year, 2 years, 3 years, and 4 years, with a CBCT scan specifically conducted at 6-month follow-up. Through the reconstruction of three-dimensional cone beam computed tomography (CBCT) data, an early prognosis was facilitated by monitoring changes in lesion volume. Various treatment predictors-including sex, type of treatment, lesion size, preoperative pain, jaw, type of teeth involved, sealer extrusion, and the number of root canals-were meticulously analyzed. The evaluation of post-treatment outcomes leveraged both clinical observations and radiographic data collected during the follow-up periods. The Kruskal‒Wallis test and one-way ANOVA were also conducted to determine the independent factors influencing treatment outcomes. A significance level of 5% was established.
RESULTS: Thirty-five teeth from 35 patients with a median age of 28 years (range 24-34) were treated; the median follow-up duration was 19 months (range 12-26). The overall success rate was 91.4%, with a median lesion reduction of 77.0% (range 54.2-96.4%) at 6 months. Patients under 30 years of age exhibited a significantly greater success rate than older patients did (100.0% vs. 80.0%, p = 0.037). Other factors, such as sex, jaw, treatment type, preoperative pain, cyst size, tooth location, sealer extrusion, and the number of roots, did not significantly impact treatment outcomes.
CONCLUSIONS: Despite limitations related to the observational case-series study design and relatively small sample size, our findings suggest that utilizing the ANPI in the NSRCT for LCPLs may hold promise. The notably higher success rate in patients younger than 30 years is worth noting.
The invention discloses a medicament for treating pancreatic cancer. The medicament has a relatively high curative effect, and the effective rate of the medicament for treating the pancreatic cancer can reach more than 90%. The pancreatic cancer is relatively infrequent in malignant tumors of alimentary tract. According to modern medicine, patients subjected to benign pancreatic cancer are less, malignant pancreatic cancer accounts for 10% of malignant tumors and mainly occurs in groups at the age of 40 to 60, men suffering from the malignant pancreatic cancer are 4 times more than women suffering from that, and the pancreatic cancer mainly occurs at a pancreatic head and rarely occurs at a pancreatic body and a pancreatic tail part. Most of the pancreatic cancers come from the epithele of a pancreatic duct. The benign pancreatic tumor is possibly subjected to canceration. The pancreatic cancer is relatively rapid in development, easy to transfer and relatively short in disease course.
Cardiovascular disease is the leading cause of death in renal transplant recipients (RTR). 44% of RTR have LDL-C greater than 100mg/dL, six months after transplant. The correlation between the increase in serum LDL level and the increased risk of atherosclerotic cardiovascular disease (ASCVD) is well established. A reduction in LDL level is associated with a decreased risk of mortality and morbidity in patients with ASCVD. Statins have been the long-standing drug of choice in treating dyslipidemia. A single prospective randomized trial known as the ALERT trial compared the benefits of statins to placebo in transplant recipients. The original study consisted of 2000 RTR and an extension of this study evaluated 1652 patients and demonstrated a 21% reduction in major cardiac events (p=0.036) and a 29% reduction in cardiac death or definite non-fatal myocardial infarction (p=0.014). Even though statins decrease the probability of cardiovascular events there was no difference in graft survival or mortality benefit in RTR. Another concerning factor for the use of statins is the tolerability of these drugs. Statins have been associated with hepatotoxicity and myotoxicity, the incidence of which is higher in RTR. This effect is dose-related and may be precipitated by the administration of agents that inhibit cytochrome p450 isoenzymes such as Tacrolimus and Cyclosporine which are the most commonly used immunosuppressants. Another statin based drug (Fluvastatin) has been associated with proteinuria and renal failure. Hence there is a need to explore novel treatment options in the management of dyslipidemia, particularly in RTR. PCSK-9 inhibitors (Proprotein Convertase Subtilisin Kinase-9 inhibitors) have shown to decrease LDL levels by 60% in patients on statin therapy. However, these drugs have been studied sparingly in patients with Chronic Kidney Disease (CKD) and have not yet been analyzed in RTR.

The study will involve 120 patients across 3 different hospitals. Two different but equivalent drug dosing strategies are available. A 420mg monthly subcutaneous injection using an on-body infusor (Repatha Pushtronex system) or a 140mg subcutaneous injection once every two weeks using a prefilled auto-injector (Repatha SureClick). The choice of dosing strategy will be based on patient preference. This study will be conducted over one year.
BACKGROUND: Vitreous floaters are a common ocular condition that affects individuals of all ages. Although vitreous floaters are typically benign, they can significantly impair visual acuity and quality of life. Laser vitreolysis, which uses an Nd: YAG laser to vaporize collagenous vitreous opacities, is increasingly being used as a treatment option. However, there is currently a lack of evidence regarding its efficacy and the appropriate timing of its application. This study aims to evaluate the efficacy and safety of early intervention with YAG laser vitreolysis in treating symptomatic vitreous floaters.
METHODS: The present study is a randomized, controlled, double-blind clinical trial. A total of 70 participants with symptomatic floaters for 1 month were prospectively recruited. These participants will be randomly assigned to two groups, with 35 individuals in each group: the early treatment group and the delayed treatment group. Participants assigned to the early treatment group will undergo YAG laser vitreolysis immediately, followed by a sham laser treatment 3 months later. On the other hand, participants assigned to the delayed treatment group will receive a sham laser treatment and then undergo YAG laser vitreolysis 3 months later. The follow-up time points will be 1, 3, 6, and 12 months from randomization. Primary outcomes will be participants' self-reported improvement in visual disturbance on a scale of 1 to 10 and their scores on the National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25). Secondary outcomes will be an objective evaluation of the effectiveness of the treatment in reducing vitreous floaters through OCT and fundus photography and tracking any adverse events related to the eyes or overall health.
DISCUSSION: This clinical trial aims to evaluate the effectiveness of YAG laser vitreolysis in treating symptomatic vitreous floaters and assess the safety of performing early intervention with YAG laser vitreolysis.
TRIAL REGISTRATION: ClinicalTrials.gov NCT05800353 . Registered on 10 March 2023.
A luminaire is provided, having an enclosure and a chamber air coupled to the enclosure. The enclosure includes luminaire components that emit a light beam, has an opening, and is otherwise sealed. The chamber includes a drying agent, two openings, and is otherwise sealed from the external air. One opening of the chamber is coupled by a sealed air coupling to the opening of the enclosure. The other opening of the chamber is completely covered by a membrane that allows air to pass through the material while reducing the passage of water droplets in the air. The enclosure may include sensors that measure air pressure, air humidity, and/or air temperature of the enclosure. The luminaire may include a control system configured to collect data from the sensors and to send information related to the collected data to a user of the luminaire via a communication channel.
No dosage adjustment for ONGLYZA is recommended for patients with mild renal impairment (creatinine clearance [CrCl] >50 mL/min).

The dose of ONGLYZA is 2.5 mg once daily for patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD) requiring hemodialysis (creatinine clearance [CrCl] ≤50 mL/min) [see Clinical Pharmacology (12.3) and Clinical Studies (14.3)]. ONGLYZA should be administered following hemodialysis. ONGLYZA has not been studied in patients undergoing peritoneal dialysis.

Because the dose of ONGLYZA should be limited to 2.5 mg based upon renal function, assessment of renal function is recommended prior to initiation of ONGLYZA and periodically thereafter. Renal function can be estimated from serum creatinine using the Cockcroft-Gault formula or Modification of Diet in Renal Disease formula. [See Clinical Pharmacology (12.3).]
This is an open label trial using standard 3+3 design, in up to 24 HSV seropositive subjects. This rule-based design proceeds with cohorts of three patients.
Children in this arm will play the computer game which was developed by the researcher team 3 session/weeks for 5 weeks. Each session will last for 40 minutes.
The rapid emergence of resistant HIV strains has been observed in patients receiving monotherapy with a nucleoside analog or non-nucleoside reverse transcriptase inhibitor. Use of combination therapy with two nucleoside drugs or convergent combination therapy with two nucleosides and a non-nucleoside RT inhibitor may minimize the evolution of these resistant HIV strains. Since toxicity is a major problem in patients with advanced disease who are receiving combination nucleoside therapy, alternating the two drugs may provide a way of retaining several benefits of combination therapy while minimizing the increased toxicity.

Patients are randomized to receive either AZT/ddC, AZT/ddI, AZT alternating monthly with ddI, or AZT/ddI/nevirapine. Patients are evaluated at week 0 and every 4 weeks thereafter for 2 years. Pharmacologic, virologic, and macroneurologic substudies will be conducted. Patients who are already enrolled on protocol ACTG 193 will be given the option of continuing on their originally assigned ACTG 193 therapy for an additional 6 months or undergoing re-randomization to one of the four treatment arms on ACTG 193A.
Implantable, pressure adjustable diaphragm pump systems which are scalable and are characterized by a common type of actuating mechanism. The pumps may be inductively and transcutaneously powered via adjacent, mutually inductive electromagnetic coils. Alternatively the pumps may be effectively “self” powered using a synthetic muscle attached to a local bending or twisting force. The pumps may be used in a range of applications from mechanical applications to medical applications such as intraocular pressure control for glaucoma patients, bodily fluid drainage control, and drug delivery systems. These pump systems each include a pumping chamber having an anterior end attached to an implantable influent conduit. In the case of an ocular pressure control device, the influent conduit is inserted into the anterior chamber of the eye. A flexing ionic polymer conductor composite IPCC synthetic muscle, which is a type of ionic polymer metal composite (IPMC) synthetic muscle, functions as the primary actuator. The posterior end of the pumping chamber is connected to an effluent or drainage conduit, which may drain bodily fluids or dispense drugs to an area of the body. A key feature of the invention is the self or secondary power generation system in the form of a much larger piece of IPCC synthetic muscle which, in the case of glaucoma prevention systems, may be placed on the globe surface (sclera) of the eye and attached to and secured by the extraocular muscles of the eye. An alternative external power system includes a biocompatible induction coil with gold wire armature that can be transcutanously activated, adjusted, and computer-interrogated and controlled by a surgeon. The device of the invention is further equipped with a pair of adjustable variable flow valves placed at the juncture of the inlet and effluent conduits with the pumping chamber. The valves are used to regulate fluid flow through the pumping chamber. A pressure regulating system including a pressure sensor and pump controlling microprocessor may also be used with the inventive system.
PROBLEM TO BE SOLVED: To obtain the subject preparation capable of increasing percutaneous absorption of low-molecular weight active ingredient containing skin lotion, etc., by applying to the skin before using skin lotion, etc., by formulating a polar oil solution having percutaneous absorption-promoting effect. SOLUTION: This skin treatment agent is obtained by formulating a polar oil solution having percutaneous absorption promoting effect. A higher fatty acid such as isostearic acid, a vegetable oil such as olive oil, terpenes such as limonene, triglycdride such as glyceryl 2-ethylhexanoate, an ester oil such as isoprolyl myristate is exemplified as the polar oil solution. The formulating amount of the polar oil solution is preferably 0.01-10 wt.% based on total amount of the objective preparation. The preparation can be applied to medicines, cosmetics, etc. pH of the preparation is preferably 6-8. Furthermore, coloring pigment, a antiseptic agent, a surfactant, an antioxidant, a biopolymer, etc., can be formulated in the skin treatment agent.
Designed with a Patient and Public Involvement Team, DaRe2THINK is an individual-patient, open-label, event-driven randomised trial with 1:1 allocation to DOAC or no additional therapy (usual care). Automated screening will occur of over 12 million patients in England, with targeted recruitment to practices with eligible patients, regular updates to General Practitioners, simple processes for centre inclusion and patient randomisation, remote e-consent and no additional visits for any patient. The primary outcome is a comprehensive composite of any thromboembolic event, ascertained entirely using electronic healthcare records within both primary and secondary NHS care across the nation. All endpoint data will follow a pre-published coding manual for extracted electronic healthcare data. The key secondary outcome is the change in patient-reported cognitive function, using remote technology solutions to save time for clinical staff and patients. DaRe2THINK will carefully assess and validate safety outcomes relating to major and minor bleeding. A systematic health economic analysis will determine NHS and societal cost-effectiveness of DOAC therapy in this younger population of patients with AF. DaRe2THINK will initially run over a 5-year period (outcomes as listed below), with longer-term outcomes (in particular cardiovascular death, cognitive function and vascular dementia) reassessed at 10 years.
FIELD: medicine, phytotherapy, pharmacy, homeopathy. SUBSTANCE: invention relates to the development of technology for preparing homeopathic medicinal agents based on vegetable base as tablets. Method involves preparing the following plant tinctures using 70% ethyl alcohol as an extractant: Jungarian monkshood roots, peppermint flowers and leaves, bryony roots, deadly nightshade flowers and leaves, common lady's mantle above ground part, mullein flowers and leaves, mezereon above ground part and coneflower above ground part. Raw is milled to particles size 2-5 mm. The ratio raw to extractant = 1: 10. Then honey bee bodies 10% tincture is prepared using 70% ethyl alcohol as an extractant. Then tincture is mixed in equal ratios and mercuric chloride in dilution 10 -3  is added to the prepared mixture. Mixture is applied on granules representing a mixture of sugar powder with gelatin solution by spraying method in quasi- liquid system. Granules are dried at temperature 45-50 C, tableted with addition of calcium stearate and sublingual medicinal formulation with mass 0.25 g is obtained. Invention provides the high pharmacological effect. EFFECT: improved preparing method, valuable medicinal properties of agent. 1 ex
1. Technical Result Widening of assortment of means for treatment of bones and joints inflammatory diseases, increase in treatment efficiency. 2. Essence A means comprises fruits of plant Maclura pomifera, leaves of pant Thuja occidentalis, aqueous-alcoholic infusion of acacia flowers Robinia pseudoacacia, bay leaf oil Laurus nobilis L., lemon oil Citrus limon L., bee wax and goat fat. 3. Field of Application Medicine.
Phenobarbital is a barbituric acid derivative for oral administration and occurs as a white, odorless, slightly bitter powder that is soluble in chloroform, freely soluble in alcohol or ether, and slightly soluble in water. Its saturated solution has a pH of about 5.6. Chemically, it is 5-ethyl-5-phenylbarbituric acid with the molecular formula C12H12N2O3 (232.24). The structural formula is as follows:

Each Phenobarbital Tablet, USP contains 15 mg, 30 mg, 60 mg or 100 mg of phenobarbital, USP. Inactive ingredients are as follows:  
15 mg, 30 and 60 mg: Calcium Stearate, Colloidal Silicon Dioxide, Corn Starch, and Microcrystalline Cellulose.  
100 mg: Anhydrous Lactose, Colloidal Silicon Dioxide, Corn Starch, Docusate Sodium, Lactose Monohydrate, Magnesium Stearate, Microcrystalline Cellulose, and Sodium Starch Glycolate.
In the intervention group, mothers will be asked to provide at least 1 feed of fresh milk (i.e. within 4 hours of milk expression) per day.Other time, feed frozen milk.
Patellofemoral pain syndrome (PFPS) is a frequent musculoskeletal pathology affecting population like adults, teenage boys/girls, military and athletic individuals. It is a probable reason for anterior knee pain in individuals, also known as runner's knee. It is mainly defined as the individuals experience anterior knee pain, including other structural pathology like of patella and retinaculum. There is no related problem of intra articular and peri-patellar impairments. The causes of PFPS includes muscular imbalance of vastus lateralis and vastus medialis, maltracking of patella, instability of hip joint and hind most foot eversion. According to literature the PFPS is mostly common in active young population along with that women are more prone to develop this disease condition as compare to males because of their pelvis anatomy. Wider pelvis area in women causes more stress on knees. The reason of knee joint pain in older people is arthritis (age related degenerative changes). KT tapping has elastic properties like skin, stretching 30 % to 40 % stretching lengthwise. KT has water proof qualities and can be applied for 3 to 5 days. By applying KT over the skin of affected muscle or on joint surface, it reduces the pain, improves the circulation by giving positional impulse through skin, and modify interstitial tissue to reduce skin tension. Mulligan introduced a tapping technique called Mulligan tapping along with Mobilization with Movement technique development. Mulligan tape method prevents the positional malalignment in the joint. Tape may be applied for a week or two and not cause any harm along with mobilization Literature review: Anne Hickey et al. conducted a study in Australia in 2016. In this study effects of mulligan knee tapping technique on pain and lower limb biomechanics was determined. The study concluded that the technique successfully reduced the knee pain, decreased hip internal rotation and active gluteal muscles earlier. Leticia Lopes Aguiar et al. conducted a study in which he determines the effect of mulligan concept among ballet dancers. The study concluded that mulligan concept had significant results to improve pain threshold. Samara Alencar Melo et al. in which KT taping effects was determined on pain and muscular performance in patellofemoral pain syndrome patients did a study in 2018. In this RCT, the results showed that KT causes reduction in pain within 72 hours after its application without causing tension around skin. In 2017, Neelam Rehman et al. in Pakistan conducted a study. In this research the immediate effects of KT on pain in athletic population having PFPS was determined. The study concluded that KT had immediate effects in reducing pain and it can be used to treat immediate post injuries in athletic population.